<code id='274C11369D'></code><style id='274C11369D'></style>
    • <acronym id='274C11369D'></acronym>
      <center id='274C11369D'><center id='274C11369D'><tfoot id='274C11369D'></tfoot></center><abbr id='274C11369D'><dir id='274C11369D'><tfoot id='274C11369D'></tfoot><noframes id='274C11369D'>

    • <optgroup id='274C11369D'><strike id='274C11369D'><sup id='274C11369D'></sup></strike><code id='274C11369D'></code></optgroup>
        1. <b id='274C11369D'><label id='274C11369D'><select id='274C11369D'><dt id='274C11369D'><span id='274C11369D'></span></dt></select></label></b><u id='274C11369D'></u>
          <i id='274C11369D'><strike id='274C11369D'><tt id='274C11369D'><pre id='274C11369D'></pre></tt></strike></i>

          knowledge

          knowledge

          author:explore    Page View:1778
          John Thune raises one hand while speaking to the press at the Capitol 2024 — politics coverage from STAT
          Sen. John Thune is one of a group of lawmakers that is working on 340B reform legislation. BRENDAN SMIALOWSKI/AFP via Getty Images

          WASHINGTON — A bipartisan group of senators released a draft of legislation to resolve controversial disputes in the 340B drug discount program, according to documents obtained by STAT.

          The drug discount program, which was designed to support providers that serve low-income patients, has been increasingly contentious as it’s grown in recent years. The draft legislation makes a number of changes to address some of the most controversial points, including its rules over so-called “contract pharmacies” and which subsidiaries can qualify for discounts.

          advertisement

          The draft would also require more oversight, and it would give the Health Resources and Services Administration more money to do it with a new user fee program. Providers would pay HRSA up to 0.1% of the savings it receives from the program.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In
          Previous article: Testing GLP
          Next article: How to save PrEP access — and even expand it

          focus

          DIEP, the 'gold standard' of breast reconstruction, is under threat
          DIEP, the 'gold standard' of breast reconstruction, is under threat

          AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

          read more
          An innovative path out of biotech’s “valley of death”
          An innovative path out of biotech’s “valley of death”

          AdobeSomanypromisingmedicalinnovationsneverreachtheirfullpotentialastherapiesorcures,languishinginst

          read more
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

          CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

          read more

          Readout Newsletter: Illumina, CRISPR, Regeneron

          AdobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyo